Agilent Technologies reported third-quarter adjusted earnings per share of $1.62, exceeding the $1.49 estimate by $0.13, while revenue totaled $1.88 billion against a $1.84 billion consensus. The life sciences and diagnostics company posted adjusted EPS of $1.62, up 18% year-over-year, driven by strong demand in biopharma and applied markets.
Revenue rose 11% to $1.88 billion, ahead of the $1.84 billion estimate, with growth across all segments. The company’s guidance for fiscal 2026 was raised to an adjusted EPS range of $6.18 to $6.21, up from prior guidance and above the current analyst consensus of $6.06. Agilent also provided a revenue outlook of $7.9 billion to $8.0 billion for the year.
The stock closed at $155.08, up 14.42% over the last three months and 30.66% over the past year. Analysts have revised earnings estimates modestly, with three positive revisions and eight negative revisions over the last 90 days. Agilent’s financial health score, as assessed by InvestingPro, is rated as "good performance."
